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Introduction
Disturbances in glucose homeostasis are increasingly recognized as one of the most relevant adverse effects of antibacterial fluoroquinolones. Both, hypoglycemic and hyperglycemic episodes occur during therapy [1, 2] . Hypoglycemias are rare, however, they are potentially life-threatening and have led to a number of fatalities [2] . While some of the hypoglycemic episodes have to be attributed to an interaction with sulfonylurea antidiabetic drugs [3] [4] [5] , it is generally accepted that fluoroquinolones by themselves can induce hypoglycemias and concomitant sulfonylurea therapy is an independent risk factor [6] .
The characterization of a direct insulinotropic effect of fluoroquinolones on isolated rat pancreatic islets led to the hypothesis that a block of B-cell K ATP channels was responsible for this effect [7] . It is generally agreed that the pharmacological closure of K ATP channels leads to a depolarization of the B-cell plasma membrane and influx of calcium via voltagedependent calcium channels, which in turn activates the exocytotic machinery [8] . However, the secretion elicited by the increase in the cytosolic free calcium concentration ([Ca 2+ ] i )
remains modest if there is no concomitant increase in energy metabolism as is produced by glucose, the main physiological stimulus. By as yet unidentified signals the glucose metabolism of the B-cell strongly amplifies the secretion initiated by the Ca 2+ signal. Thus, the stimulus secretion coupling in pancreatic B-cells can be viewed as a bifurcating pathway, one branch being K ATP channel-dependent, the other K ATP channel-independent. These branches are also referred to as triggering and amplifying pathways, respectively [9] .
It could be shown that two fluoroquinolones, lomefloxacin and norfloxacin, inhibited K ATP channel activity in insulin-secreting RINm5F cells [10] . Following the above outlined view on stimulus-secretion coupling in B-cells, the fluoroquinolones should thus be able to initiate insulin secretion. The K ATP channel block was due to a direct effect at the poreforming subunit Kir6.2 [11] , whereas sulfonylureas, the classical blockers of K ATP channels, which are used as oral antidiabetic drugs, act via binding to the regulatory subunit SUR1 [12] .
The observation that gatifloxacin and temafloxacin, which were more potent than levofloxacin to block the K ATP channel were also more effective to increase the insulin release from statically incubated mouse islets [11] further supported the hypothesis that block of this channel is responsible for the hypoglycemias.
However, there are inconsistencies. While case reports of hypoglycemias exist for a number of fluoroquinolones, pharmacoepidemiologic evidence clearly documents an outstanding role of gatifloxacin as an inducer of hypoglycemias [1, 2] . Since in one large trial the risk of other fluoroquinolones was found not to be different from that of other antibacterial drugs it has been supposed that the induction of glucose abnormalities is not a class effect of fluoroquinolones [1] . Also, the fluoroquinolones norfloxacin and levofloxacin were found to be only weakly effective as K ATP channel blockers [10, 11] , but nevertheless there are case reports linking these compounds to severe and even lethal hypogycemias [13, 14] , which 4 raises the question as to whether there are unidentified triggering factors. Finally, gatifloxacin is also associated with the induction of hyperglycemic episodes in diabetic and non-diabetic patients [15, 16] . The hyperglycemic episodes, which are even more frequent than the hypoglycemic episodes [1] are not easily explained by a block of K ATP channels [17] .
By studying the insulinotropic effects of an array of fluoroquinolones comprizing clinically relevant and structurally systematically varied compounds ( Fig. 1) and by comparing these effects with those on membrane potential and [Ca 2+ ] i we sought to answer the following questions: i) Is the stimulation of insulin secretion a group effect of fluoroquinolones? ii) Is the insulinotropic effect dependent on the block of K ATP channels or are K ATP channelindependent mechanisms involved? iii) Can structural features be identified which confer the insulinotropic effect?
Materials and methods

Chemicals
Gatifloxacin was kindly provided by Grünenthal (Aachen, Germany), ciprofloxacin and moxifloxacin were bought as solutions for i.v. use. The N1-aryl fluoroquinolones (1-(4-
(piperazine-4-yl)-3-quinolinecarbonic acid = C4) were synthesized as described earlier [18] .
Lomefloxacin, norfloxacin and diazoxide were obtained from Sigma (Taufkirchen, Germany), tolbutamide from Serva (Heidelberg, Germany), efaroxan from Tocris (Bristol, UK), and D600 (methoxyverapamil) from Knoll (Ludwigshafen, Germany). Collagenase P for pancreatic islet isolation was supplied by Roche Diagnostics (Mannheim, Germany), Fura-2/AM by Molecular Probes (Leiden, The Netherlands), cell culture medium RPMI 1640 by was from Gibco/Invitrogen (Karlsruhe, Germany) and fetal calf serum from PAA (Cölbe, Germany). All other reagents of analytical grade were from E. Merck (Darmstadt, Germany).
Tolbutamide stock solutions were prepared in 0.1 N NaOH.
Tissue
Islets were isolated from the pancreas of NMRI mice or SUR1 Ko mice (12 -16 weeks old, fed ad libitum) by a collagenase digestion technique and hand-picked under a stereomicroscope. Single cells were obtained by incubation of the islets for 10 min in a Ca 2+ -free medium and subsequent vortex-mixing for 1 min. Single islet cells were cultured on glass cover slips for up to 4 days in cell culture medium RPMI-1640 with 10 % fetal calf serum (5 mM glucose) in a humidified atmosphere of 95% air and 5% CO 2 at 37°C.
Measurement of insulin secretion.
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according to the instructions of the manufacturer.
Electrophysiological Recordings
Pipettes were pulled from borosilicate glass (2 mm o.d., 1.4 mm i.d., Hilgenberg, Malsfeld, Germany) by a two-stage vertical puller (List Electronic, Darmstadt, Germany ) and had resistances between 3 and 6 MOhm when filled with solution. Currents and voltages were recorded by an EPC 7 patch-clamp amplifier (List Electronic), and low pass-filtered by a 4-pole Bessel filter at 2 kHz and stored on a video tape. The membrane potential of B-cells was determined using the whole-cell and perforated patch modes under current clamp condition.
The patch perforation was achieved by 100 µg/ml nystatin in the pipette solution [19] .
Exposure to the test compounds and and wash-out was done by a slow bath perfusion system.
The compositions of the bath and pipette media were as given by Zünkler et al. [20] . The glucose concentration of the extracellular solution was 0 mM in the whole cell mode and 5 mM in the perforated patch mode. All experiments were performed at room temperature (20 -23 °C) . Data were analysed off-line using pClamp 6.03 software (Axon Instruments, Foster City, CA, USA).
Microfluorimetric Measurements of the Cytosolic Ca 2+ -Concentration ([Ca 2+ ]i)
Islet cells were cultured on glass cover slips in Petri dishes and were used from day 2 to 4 after isolation. Fura-2/AM was loaded at a concentration of 2 µM for 35 min at 37 °C. 
Results
Insulinotropic effect in the presence of a stimulatory glucose concentration
Since earlier measurements of the K ATP channel activity had shown that lomefloxacin, but not norfloxacin had a considerable blocking effect [10] , these two fluoroquinolones were initially selected for a comparison of the insulinotropic activity. Islets were perifused with both drugs in sequence. Lomefloxaxin elicited a 3fold increase within 15 min (Fig. 3A) . After a wash-out period of 20 min, prestimulatory secretion levels were practically re-established and 100 µM norfloxacin were added to the perifusion medium. Norfloxacin proved to be devoid of an insulinotropic effect. The same was true when the islets were exposed to these fluoroquinolones in a reverse order (Fig. 3A) . Since a steady state of the lomefloxacin effect was apparently not achieved after 15 min, the drug perifusion time was prolonged to 30 min.
Here, 100 µM lomefloxacin enhanced the insulin secretion 4.5fold, whereas 100 µM norfloxacin had still no effect (data not shown).
In the next set of experiments the insulinotropic effect of the clinically relevant fluoroquinolones gatifloxacin, ciprofloxacin and moxifloxacin was characterized. In the presence of 10 mM glucose 100 µM gatifloxacin showed a clear enhancing effect on insulin secretion whereas the effect of ciprofloxacin and moxifloxacin was less obvious. However, after normalization of the data ( The relevance of specific substituents for the insulinotropic effect was further assessed by including a number of systematically varied N1-aryl fluoroquinolones. While compound C2 proved to be strongly effective in the presence of 10 mM glucose, all other compounds of this series (C1, C3, C4) had only a moderate stimulatory effect. The secretion rates produced by these weakly effective compounds were still increasing at the end of the 30 min exposure time, suggesting that a steady state had not yet been reached (Fig. 3C ).
Glucose-dependency of the insulinotropic effect
Gatifloxacin, ciprofloxacin and moxifloxacin were used to assess the glucose dependency of the insulinotropic effect. For the first 90 minutes, the islets were perifused with Krebs-Ringer medium containing 5 mM glucose. During the exposure to the fluoroquinolones, from 90 min to the end of the perifusion, the glucose concentration was increased to 10 mM. In the presence of 5 mM glucose, all of the fluoroquinolones were virtually devoid of an insulinotropic effect. When the glucose concentration was increased to 10 mM all compounds clearly enhanced the biphasic secretion elicited by the increased glucose concentration (Fig. 4A ). When the data were normalized with respect to the secretion rate before exposure to the fluoroquinolones (Fig. 4B ), ciprofloxacin and gatifloxacin were more effective than moxifloxacin, which was more effective than control (area under the curve for the time period 90 to 125 min, p  0.05, t-test). In the presence of 30 mM glucose a 30 min perifusion with 100 µM gatifloxacin had no significant enhancing effect, whereas a subsequent depolarization by 40 mM KCl was clearly effective (data not shown).
Lack of a K ATP channel-independent insulinotropic effect
The question whether the K ATP channel block is indispensable for the insulinotropic effect was investigated by comparing the insulin release from normal NMRI mouse with that from SUR1 Ko islets. Within 20 min 100 µM lomefloxacin increased the secretion of NMRI mouse islets in the presence of 10 mM glucose to 430 %. Similarly, 100 µM C2 increased secretion to 320 % of the prestimulatory rate ( Fig. 5A ). However, both compounds proved to be ineffective to enhance secretion of SUR1 Ko islets ( 
Fluoroquinolone-induced depolarization of the B-cell plasma membrane
Typically, the increase of [Ca 2+ ] i initiating exocytosis is linked to the block of K ATP channels via the depolarization of the plasma membrane, which was initially measured by patch clamping in the conventional whole cell mode. The fluoroquinolone-induced depolarization was slow, often only apparent after a lag time. Wash-out revealed a poor reversibility. These characteristics applied to all fluoroquinolones ( Fig. 6 , Table 1 ). In contrast, depolarization by tolbutamide in the same experiments showed the typical fast onset and offset before and after exposure to the fluoroquinolones ( Fig. 6C and D) . However, diazoxide was nearly ineffective to antagonize the fluoroquinolone-induced depolarization (Fig. 6C ).
As expected, lomefloxacin was clearly more effective than norfloxacin (Table 1) .
Among the clinically important compounds gatifloxacin and ciprofloxacin at 50 µM were highly effective (depolarization by 28.5 mV and 25.4 mV, respectively), but moxifloxacin depolarized only by 8.6 mV (Table 1) . When the concentration was increased to 100 µM, however, moxifloxacin decreased the membrane potential by further 11.8 mV, whereas only a modest further increase occurred with gatifloxacin and ciprofloxacin ( Fig. 6A and B).
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Increasing the concentration to 100 µM resulted in a further depolarization by 16 mV with C1, but only by 4 to 6 mV with C2, C3, and C4. The rank order of efficacy at 50 µM was: C2  C1 = C3  C4 and was practically unchanged at 100 µM (C2 = C1  C3  C4).
Fluoroquinolone-induced depolarization of intact B-cells
The depolarizing effect of ciprofloxacin, gatifloxacin and moxifloxacin was also tested in metabolically intact B-cells, i.e. using the perforated patch configuration of the patch-clamp technique. When the bath medium contained a basal glucose concentration (5 mM), neither gatifloxacin, nor ciprofloxacin nor moxifloxacin (all tested at 100 µM) had any significant effect on the plasma membrane potential. In the same set of experiments, the sulfonylurea tolbutamide (500 µM ) and the imidazoline efaroxan (100 µM) markedly depolarized the Bcell membrane ( Fig. 7A and B ). Of note, efaroxan was effective in the presence of gatifloxacin and ciprofloxacin and diazoxide antagonized its effect (Fig. 7 ). Only at 500 µM, gatifloxacin induced a depolarization with action potential spiking (Fig. 7C ). In principle, the same response was seen with 500 µM moxifloxacin, although the spiking episodes were less frequent. There was no depolarization by 500 µM ciprofloxacin. The depolarization by gatifloxacin and moxifloxacin could be completely antagonized by 300 µM diazoxide (not shown).
Fluoroquinolone-induced increases of [Ca 2+ ] i
At the beginning of each experiment, the Fura-loaded and the sham -loaded islet cells were exposed to a strongly depolarizing K + concentration, which served as an internal standard to assess the magnitude of the [Ca 2+ ] i increase caused by the subsequent perifusion with the fluoroquinolones (Fig. 8 ). diminished by the addition of D600 (data not shown).
In B-cells from SUR1 Ko islets lomefloxacin, gatifloxacin (Fig. 8C ) and C2 increased the net Fura ratio. In each case D600 caused a clear reduction. Wash-out of the fluoroquinolones led, after a marked transient reduction, to a minor reduction which was not affected by the wash-out of D600. The values at the end of the perifusion corresponded to those at the beginning.
Fluoroquinolone-induced increases of [Ca 2+ ] i at basal glucose concentration
In the presence of 5 mM glucose 100 µM gatifloxacin did not cause an increase in the [Ca 2+ ] i levels whereas 40 mM KCl was effective when added prior to gatifloxacin and also when added during the gatifloxacin perifusion (Fig. 9A) . When the gatifloxacin concentration was raised from 100 to 500 µM in the presence of 5 mM glucose a clear increase in [Ca 2+ ] i was observed The comparatively large SEM ranges of this response are due to heterogeneity at the single cell level (Fig. 9B ).
Discussion
This study shows that the enhancement of insulin secretion is a group effect of fluoroquinolones and depends on their ability to block K ATP channels in pancreatic B-cells.
Structurally, it is determined by a combination of several substituents which may affect both membrane permeability and target affinity. Surprisingly, the fluoroquinolones did not initiate insulin secretion, but rather enhanced the secretory response when the glucose concentration was stimulatory by itself. Theoretically, this feature precludes an inappropriate insulin secretion in the presence of a basal glucose concentration and would be a desirable property of an antidiabetic agent. It is thus necessary to assume that as yet unidentified factors may exist which potentiate the insulinotropic effect in the presence of a basal glucose concentration and finally induce hypoglycemia.
Characteristics of fluoroquinolone-induced insulin secretion
The effect of the clinically relevant fluorquinolones, gatifloxacin, ciprofloxacin and moxifloxacin, was initially characterized in the presence of 10 mM glucose, because this moderate stimulatory glucose concentration amplifies the response to non-nutrients [9] and thus permits easier detection of different efficacies. The rank order of efficacy was:
gatifloxacin > moxifloxacin > ciprofloxacin > control. However, the secretion caused by moxifloxacin or ciprofloxacin was still increasing at the beginning of the wash-out period. In
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Surprisingly, none of the fluoroquinolones stimulated insulin secretion in the presence of a basal glucose concentration (5 mM), but raising the glucose concentration from 5 to 10 mM revealed the insulinotropic effect. Thus, the insulinotropic effect of the fluoroquinolones is not an initiation of insulin secretion, but rather an enhancement of the stimulatory effect of B-cell nutrients. Our observation is in apparent contrast to data of Saraya et al [11] who had found a stimulatory effect of 300 µM gatifloxacin or temafloxacin on mouse islets in the presence of 5.5 mM glucose. Similar to our results, Maeda et al. [7] found no effect of 100 µM lomefloxacin on rat islets in the presence of a basal glucose concentration (3 mM), but a threefold increase was noted when lomefloxacin was used at the exceedingly high concentration of 1 mM. The glucose dependence of the insulinotropic effect may therefore be a concentration-dependent phenomenon. In principle, such a dependence on the presence of nutrient secretagogues also applies for the insulinotropic effect of the sulfonylureas, the prototypical class of K ATP channel blockers [21] , but it is generally agreed that sulfonylureas stimulate insulin secretion in the presence of a basal glucose concentration and, at high concentrations, even in the absence of glucose [22] .
Another unexpected observation was that the three clinically relevant compounds appeared to be similarly effective as enhancers once the glucose concentration was raised to a stimulatory level. This in marked contrast to the initial experiments where the glucose concentration was kept constant at 10 mM, most likely because in these experiments the perifusion time was to short permit a steady state with each compound. We thus conclude that at 100 µM all three fluoroquinolones are in principle effective enhancers of insulin secretion, moxifloxacin being somewhat less effective than cipro-and gatifloxacin. In fact, in earlier clinical pharmacological studies on healthy and diabetic individuals, gatifloxacin was found to have the same modest effects on glucose homeostasis as ciprofloxacin and was therefore regarded as safe [23, 24] .
The inability of lomefloxacin, gatifloxacin and the N1-arylfluoroquinolone C2 to increase insulin release from SUR1 Ko islets, which do not have functional K ATP channels [25] , strongly suggests that the block of K ATP channels is indispensable for the insulinotropic effect. Fluoroquinolones may have effects on the B-cell in addition to K ATP channel blockade, but not effects which can stimulate insulin secretion independently of the K ATP channel activity. It is unclear whether the decrease of insulin content by gatifloxacin [17, 26] is such an additional effect, since sulfonylureas are also able to degranulate B-cells [27] Depolarizing effect
The B-cell membrane potential was measured as a general parameter of the triggering pathway of insulin secretion [9] . The difference between the marked depolarizing effect of lomefloxacin and the modest effect of norfloxacin in our experiments is in parallel with the
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A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 different ability to enhance insulin secretion and fits to the earlier measurements of K ATP channel activity in insulin secreting RINm5F cells, where norfloxacin was nearly ineffective [10] . Also, the comparatively slow kinetic corresponded to the kinetics of the K ATP channel block and of secretion enhancement.
However, the correspondence between KATP channel block and depolarizing effect was incomplete. E.g., fluoroquinolones C1 and C3 effectively depolarized the plasma membrane, but had only modest effects on KATP channel activity under closely similar conditions [28] . Also, there were obvious discrepancies between the depolarizing effect and the effect on secretion. E.g., the fluoroquinolone-induced depolarization was virtually irreversible, whereas the secretion enhancement showed a slow but unmistakable reversibility.
Remarkably, the KATP channel opener diazoxide, at a maximally effective concentration had at best a modest repolarizing effect, but was able to abolish the insulinotropic effect.
The results obtained in the perforated patch mode (i.e. using metabolically intact Bcells exposed to 5 mM glucose) resolved several of these contradictions. Here, 100 µM of ciprofloxacin, gatifloxacin and moxifloxacin were virtually ineffective, corresponding to the lack of insulinotropic effect at 5 mM glucose. In the same experiments, the sulfonylurea tolbutamide and the imidazoline efaroxan induced depolarizations with action potentials.
These compounds were used at a concentration which inhibits B-cell KATP channel activity by about 85% [29] , which is comparable to the effect of 100 µM gatifloxacin on reconstituted KATP channels [11] . While tolbutamide closes these channels by binding to the regulatory subunit, SUR1 [12] , efaroxan, like the fluoroquinolones, inhibits KATP channels by binding to the pore-forming unit, Kir 6.2 [29] .
The loss of potency in the perforated patch mode (as compared to the whole cell mode) may be explained by the hypothesis that the inhibition of KATP channel activity by fluoroquinolones is susceptible to negative modulation by endogenous compounds which are present in metabolically intact B-cells, but not in open B-cells (whole cell mode), where the cytosol is washed out by the pipette solution [30] . This hypothesis would also explain why diazoxide which was unable to antagonize the fluoroquinolones in the whole cell mode, but strongly antagonized the effect of gatifloxacin in the perforated patch mode, which corresponds to the secretion measurements.
In this context, the observation by Saraya et al [11] observations concur with the marked enhancing effect of ciprofloxacin and moxifloxacin on secretion when the glucose concentration was raised to a stimulatory level (Fig. 4) . [35] .
Structure -activity relations
With regard to the structure activity relationships the compounds tested in this study can be subdivided in three groups: i) compounds which have an ethyl substituent at N1, ii) cyclopropyl-substituted compounds and iii) fluorophenyl-substituted compounds. The cyclopropyl-substituted fluoroquinolones, namely ciprofloxacin, moxifloxacin and gatifloxacin, make up the clinically most relevant compounds [36] . Each of these groups 
Correlation with risk of hypoglycemia
There is only an incomplete correspondance between the present experimental data and the clinical risk of hypoglycemia. Recently, two epidemiological reports have been 13 published which permit quantitative estimates. In the first report [1] , gatifloxacin was identified to cause the vast majority of hypoglycemias with levofloxacin being a distant second. Ciprofloxacin and moxifloxacin were apparently not associated with an increased risk. In another study, evaluating spontaneous adverse events reports, gatifloxacin was again the leading cause of hypoglycemias, but there was also a sizable portion of hypoglycemias caused by moxifloxacin, levofloxacin and ciprofloxacin, roughly in the proportion of 100:10:2:1 [2] . This rank order is not reflected by the insulinotropic efficacy in vitro. The feature that sets gatifloxacin apart from the other clinically relevant compounds tested here is the comparatively fast onset of action, a feature shared with lomefloxacin and the N1-aryl fluoroquinolone C2.
The different hypoglycemic risk of ciprofloxacin, gatifloxacin, and moxifloxacin is also not explained by pharmacokinetic data. The doses which are required for antibacterial effects are similar for these three compounds. A single dose of 250 mg gave peak plasma concentrations of 1.2 µg/ml for ciprofloxacin, 1.7 and 2.2 µg/ml for gatifloxacin and moxifloxacin, respectively [37] . Since this corresponds roughly to 5 µM, it is unlikely that extracellular concentrations as high as 100 µM or 500 µM will ever occur in fluoroquinolonetreated patients. A different intracellular accumulation of the fluoroquinolones may play a role. However, it must be noted that the hypoglycemias mostly occur at the beginning of a fluoroquinolone therapy [38] , whereas after several days of therapy, when different intracellular accumulation may be more important, hyperglycemias are more frequent. While hyperglycemias may involve extrapancreatic effects [39] , our observation that the fluoroquinolones at 100 µM were ineffective to stimulate insulin secretion in the presence of a basal glucose concentration leads to the provocative question why these compounds are hypoglycemic at all. Intriguingly, diabetes is a strong risk factor, independently of a sulfonylurea or insulin therapy [40] In conclusion, it seems that the K ATP channel-blocking effect is a necessary but not a sufficient condition for the hypoglycemic side effect of the fluoroquinolones. In particular, the prominent role of gatifloxacin is not sufficiently explained. Up to a fluoroquinolone concentration of at least 100 µM, which is 20fold above the peak plasma concentrations [36, 37] , the presence of a basal glucose concentration precludes the depolarization of metabolically intact B-cells and the ensuing stimulation of insulin secretion. We hypothesize that at therapeutically relevant concentrations of the fluoroquinolones, their K ATP channelblocking effect has to be potentiated by as yet unidentified factors to stimulate insulin secretion in the presence of a basal glucose concentration and to finally induce hypoglycemia.
These factors may also be relevant for the markedly different frequency with which fluoroquinolones induce hypoglycemias. gatifloxacin. Lomefloxacin and norfloxacin contain an ethyl-substituent at N1, whereas ciprofloxacin, gatifloxacin and moxifloxacin contain a cyclopropyl-substituent at this position.
A substitution with a mono-or difluorinated aryl moiety at N1 (D) gives compounds with enhanced antituberculotic activity [41] . All of these substituents were found to be compatible with an insulinotropic effect. Methylation of the piperazinyl-moiety and substitution at C8 appear to favor the insulinotropic effect, but are not indispensable as can be seen from the effect of ciprofloxacin. A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 M a n u s c r i p t Table 1 Comparison The membrane potential of mouse pancreatic B-cells was measured in the conventional whole cell mode as shown in Fig. 6 . All compounds were tested at a concentration of 50 µM. Data are means ± SEM of the number of experiments given in brackets. All compounds were significantly effective at 50 µM (p < 0.05, unpaired t-test), except for moxifloxacin, the effect of which was marginally significant (p = 0.062). The mean time required to establish a steady state depolarization was 7.5 minutes, in control experiments (addition of 0.2 % DMSO) the membrane potential decreased spontaneously from -70.9  2.8 mV to -68.0  4.5 mV (n = 6) during this time. 
